ArticleDiscover oncology2026
A bortezomib resistance-related gene signature predicts prognosis, with ARID5B downregulation associated with poor overall survival in multiple myeloma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundResistance to the proteasome inhibitor bortezomib is a major obstacle to the treatment of multiple myeloma (MM) and a major cause of relapse and death. Investigating the role of bortezomib resistance genes in MM is crucial. This study aimed to evaluate the potential of bortezomib resistance-related genes (BRGs) as prognostic biomarkers in MM.
methodsThe transcriptome data of bortezomib resistant myeloma cell lines, as well as the gene expression and clinical data of patients were downloaded from the Gene Expression Omnibus (GEO) database. Univariate Cox and least absolute shrinkage and selection operator (LASSO) Cox regression models were employed to screen variables and construct a multigene prognostic signature based on BRGs. Single-sample gene set enrichment analysis (ssGSEA) was performed to quantify the relative infiltration levels of immune cells. The pRRophetic algorithm was utilized to assess and infer the sensitivity of anti-MM chemotherapeutics.
resultsWe identified 129 differentially expressed BRGs, with 25 associated with MM prognosis. Using the LASSO Cox regression model, we identified five key genes (IFI16, ARID5B, LTBP1, PNOC, CRIP1) and developed a bortezomib resistance model for risk stratification and prognosis prediction. Multivariate Cox regression analysis revealed that the risk score was an independent prognostic factor for overall survival (OS). Based on pRRophetic results, high-risk patients may be more sensitive to other chemotherapeutic agents, such as doxorubicin and etoposide. Additionally, we constructed a nomogram incorporating patient age, LDH, International Staging System (ISS), and BRGs, which demonstrated robust prognostic prediction capabilities. The receiver operating characteristic (ROC) values for 1-, 3-, and 5-years survival rates were 0.730, 0.734, and 0.775, respectively. We also validated the expression patterns of the five key genes in MM. IFI16 and CRIP1 expression levels were upregulated in relapsed patients, whereas ARID5B expression was decreased. PNOC and LTBP1 showed no significant differences. Notably, lower ARID5B expression was associated with poorer OS in patients.
conclusionsThe BRGs signature is a reliable biomarker for predicting the prognosis of MM and helps optimize clinical decision-making for treatment, and identifies key gene ARID5B downregulation as an adverse prognostic factor in multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.